Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PF-07242813 in healthy participants and atopic dermatitis
NCT04668066Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07242813 in atopic dermatitis (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Treatment-Emergent Adverse Events at Week 16, Treatment-Emergent Serious Adverse Events at Week 16 and 3 more. Started Dec 2020; status: completed.
02
Drugs
PF-07242813
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04668066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668066.